Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Juni 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel

HAIFA, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced it has been granted...
27. Mai 2015 03:30 ET | Quelle: Pluri Inc.

Pluristem to Present at the International Congress of Radiation Research and Chair Two Panels at the Annual Meeting of the International Society for Cellular Therapy

HAIFA, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced participation at...
25. Mai 2015 05:07 ET | Quelle: Pluri Inc.

Pluristem Issues Letter to Shareholders

HAIFA, Israel, May 25, 2015 (GLOBE NEWSWIRE) -- Dear fellow stockholders, A common objective drives our efforts at Pluristem: to bring innovative, effective treatments to patients suffering from...
19. Mai 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem to Conduct Conference at Tel Aviv Stock Exchange to Review Regulatory Progress and Company Strategy

HAIFA, Israel, May 19, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced it will conduct a...
18. Mai 2015 02:45 ET | Quelle: Pluri Inc.

Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project

HAIFA, Israel, May 18, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced a significant...
13. Mai 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem's PLX Cells One Step Closer to Entering Japan's Accelerated Pathway for Regenerative Medicine

HAIFA, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Japan's...
07. Mai 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem to Hold Symposium on Therapeutic Angiogenesis for Peripheral Arterial Occlusive Disease at European Society for Vascular Medicine in Berlin, Germany

HAIFA, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that on May 12 it...
06. Mai 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow

HAIFA, Israel, May 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has been...
04. Mai 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem to Present at Five Industry and Finance Conferences in May

HAIFA, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its executives...
20. April 2015 03:08 ET | Quelle: Pluri Inc.

Pluristem's Clinical Advisory Board Prepares Phase II Clinical Trials in Critical Limb Ischemia in Europe and Japan

HAIFA, Israel, April 20, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its Clinical...

Vorherige Seite

Nächste Seite